Machine learning-based radiomics analysis in predicting RAS mutational status using magnetic resonance imaging

[1] Ottaiano A(2021)Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol Ther Adv Med Oncol 24 1758835921989223-32

[2] Scala S(2020)Evolution of mutational landscape and tumor immune-microenvironment in liver oligo-metastatic colorectal cancer Cancers (Basel) 12 3073-665

[3] Santorsola M(2023)ESMO guidelines committee. Electronic address: clinicalguidelines@esmo.org. metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up Ann Oncol. 34 10-1505

[4] Trotta AM(2022)Delivering precision oncology to patients with cancer Nat Med 28 658-40

[5] D'Alterio C(2020)Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group Ann Oncol 31 1491-26

[6] Portella L(2020)Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives Ann Oncol 31 30-1220

[7] Clemente O(2023)KRAS pG12C mutation in metastatic colorectal cancer: prognostic implications and advancements in targeted therapies Cancers (Basel). 15 3579-126

[8] Nappi A(2023)EORTC 1409 GITCG/ESSO 01 - A prospective colorectal liver metastasis database for borderline or initially unresectable diseases (CLIMB): lessons learnt from real life. From paradigm to unmet need Eur J Surg Oncol. 49 107081-446

[9] Zanaletti N(2013)Ras mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases Ann Surg. 258 619-912

[10] De Stefano A(2018)Genetic and morphological evaluation (game) score for patients with colorectal liver metastases Br J Surg 105 1210-146

[1] Ottaiano A(2021)Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol Ther Adv Med Oncol 24 1758835921989223-32

[2] Scala S(2020)Evolution of mutational landscape and tumor immune-microenvironment in liver oligo-metastatic colorectal cancer Cancers (Basel) 12 3073-665

[3] Santorsola M(2023)ESMO guidelines committee. Electronic address: clinicalguidelines@esmo.org. metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up Ann Oncol. 34 10-1505

[4] Trotta AM(2022)Delivering precision oncology to patients with cancer Nat Med 28 658-40

[5] D'Alterio C(2020)Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group Ann Oncol 31 1491-26

[6] Portella L(2020)Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives Ann Oncol 31 30-1220

[7] Clemente O(2023)KRAS pG12C mutation in metastatic colorectal cancer: prognostic implications and advancements in targeted therapies Cancers (Basel). 15 3579-126

[8] Nappi A(2023)EORTC 1409 GITCG/ESSO 01 - A prospective colorectal liver metastasis database for borderline or initially unresectable diseases (CLIMB): lessons learnt from real life. From paradigm to unmet need Eur J Surg Oncol. 49 107081-446

[9] Zanaletti N(2013)Ras mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases Ann Surg. 258 619-912

[10] De Stefano A(2018)Genetic and morphological evaluation (game) score for patients with colorectal liver metastases Br J Surg 105 1210-146